Sientra

Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra, AlloX2, Dermaspan, Softspan and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System, consisting of a console and a handheld device which uses consumable single-use bioTips. The company was founded by Hani M. Zeini on August 29, 2003 and is headquartered in Santa Barbara, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Siena Holdings, Inc. operates as a holding American company that manages and operates an assisted care facility through its subsidiary. The private company is located in the US and has subsidiaries in the United States.

Sientra (SIEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Sientra (SIEN) Report Negative Earnings Next Week? What You Should Know

IRVINE, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Thursday, March 30, 2023. Sientra will host a conference call to discuss financial results the same day at 4:00 p.m. Eastern Time.

Sientra to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023

Data Supports Enhanced Viability of Fat in Breast Augmentation and Reconstruction Using the Viality System Data Supports Enhanced Viability of Fat in Breast Augmentation and Reconstruction Using the Viality System

Sientra Announces Preliminary Results from Clinical Study and The First Shipment of Viality™ Fat Transfer System

Aemetis

Blue Apron

Biora Therapeutics Inc

Faraday Future Intelligent Electric

Gossamer Bio Inc

Pardes Biosciences

SmileDirectClub

Tattooed Chef

Vroom

More short squeeze penny stocks to watch before February 2023. The post 10 Top Penny Stocks To Watch With High Short Interest This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Watch With High Short Interest This Week

Cemtrex

Oragenics

The Beauty Health Company

Sitio Royalties Corp

Warby Parker

Clear Secure

As much as we may recognize that short sellers perform a valuable service for the equities market, the concept of targeting short-squeeze stocks to buy just to penalize the pessimists carries cathartic value. Fundamentally, market bears operate like great white sharks.

7 Short-Squeeze Stocks to Buy Before They Soar

IRVINE, Calif., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's issued and outstanding common stock (the “Reverse Stock Split”). The Reverse Stock Split was effective at 4:00 p.m. Eastern Time on January 19, 2023. The Company's common stock is expected to begin trading on The Nasdaq Global Market on a split-adjusted basis on January 23, 2023.

Sientra Announces 1-for-10 Reverse Stock Split

IRVINE, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced that it has received approval from the United Arab Emirates Ministry of Health and Prevention to market the company's line of smooth surface, High-Strength Cohesive (HSC and HSC+) silicone gel breast implants in the United Arab Emirates. This new approval marks Sientra's third international expansion this year.

Sientra Expands Global Footprint With Regulatory Approval to Market Breast Implants in the United Arab Emirates

Sientra, Inc. (NASDAQ:SIEN ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Oliver Bennett - SVP, General Counsel & Chief Compliance Officer Ron Menezes - President, CEO Lisa Rosas - SVP, Sales and Marketing Denise Dajles - SVP, R&D and Regulatory Andy Schmidt - CFO Conference Call Participants Alex Novak - Craig-Hallum Caitlin Cronin - Canaccord Genuity Jeremy Pearlman - Maxim Group Jonathan Block - Stifel Maggie Boeye - William Blair Operator Welcome to the Sientra's Earnings Conference Call. My name is Hilda and I will be your operator for today.

Sientra, Inc. (SIEN) Q3 2022 Earnings Call Transcript

SANTA BARBARA, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the third quarter of 2022 after the close of trading on Thursday, November 10, 2022. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.

Sientra to Report Third Quarter 2022 Financial Results on November 10, 2022

SANTA BARBARA, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced the pricing of its previously announced underwritten public offering of 34,782,600 shares of its common stock (or common stock equivalents) and accompanying warrants to purchase up to an aggregate of 34,782,600 shares of common stock. Each share of common stock (or common stock equivalent) is being sold together with one warrant to purchase one share of common stock at a combined public offering price of $0.38 per unit. The warrants have an exercise price of $0.46 per share, are exercisable immediately, and will expire five years following the date of issuance.

Sientra Announces Pricing of $13.2 Million Public Offering

SANTA BARBARA, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it intends to offer and sell in an underwritten public offering, subject to market and other conditions, shares of common stock (or common stock equivalents). Each share of common stock (or common stock equivalent) will be sold with a warrant to purchase one share of the Company's common stock. The Company expects to grant the underwriter a 30-day option to purchase additional shares of common stock and/or additional common stock purchase warrants at the public offering price, less underwriting discounts and commissions. All of the securities in the offering are to be offered by the Company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Sientra intends to use any net proceeds received from this offering for general working capital purposes.

Sientra Announces Proposed Public Offering

Anticipates total third quarter net sales of $21.5-$22.5 million, up 10-15% compared to the prior year period

Sientra Announces Preliminary Unaudited Third Quarter Financial Results and Signing of Senior Secured Loan Facilities With Deerfield Management

Sientra Partners with Breast Cancer Survivor, Miranda McKeon, to Encourage Women to Take Charge of Their Breast Reconstruction Journey Sientra Partners with Breast Cancer Survivor, Miranda McKeon, to Encourage Women to Take Charge of Their Breast Reconstruction Journey

Sientra Supports Breast Cancer Awareness Month by Launching Educational Programs Designed to Empower Women

Saudi Food & Drug Authority approval propels Sientra international expansion into the GCC and Middle East region Saudi Food & Drug Authority approval propels Sientra international expansion into the GCC and Middle East region

Sientra Receives Regulatory Approval to Market Breast Implants in Saudi Arabia

Sientra, Inc. (NASDAQ:SIEN ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Oliver Bennett - Senior Vice President, General Counsel & Chief Compliance Officer Ron Menezes - President & Chief Executive Officer Andy Schmidt - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Brandon Vazquez - William Blair Jon Block - Stifel Chris Cooley - Stephens Kyle Bauser - Lake Street Capital Markets Operator Welcome to the Sientra's Earnings Conference Call. My name is Hilda, and I will be your operator for today.

Sientra, Inc. (SIEN) CEO Ron Menezes on Q2 2022 Results - Earnings Call Transcript

Lemonade

MicroVision

Sana Biotechnology

Stoke Therapeutics Inc

WeWork

Although the general rule of thumb is to avoid equities with heavy short interest, the new normal has brought with it new paradigms. One of these fresh approaches urges speculators to acquire short-squeeze stocks  in an effort to move the equities higher, forcing the bears to cover their short positions.

7 Stocks Due for a Stunning Short Squeeze

Aileron Therapeutics

Creatd Inc

Here's what you need to know about buying penny stocks on August 8th The post Penny Stocks to Buy on August 8th? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks to Buy on August 8th? 3 to Watch

SANTA BARBARA, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the second quarter of 2022 after the close of trading on Thursday, August 11, 2022. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.

Sientra to Report Second Quarter 2022 Financial Results on August 11, 2022

SANTA BARBARA, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a leading medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, was recently honored with the 2022 Supplier Horizon Award. Sientra was honored at the Annual Premier Breakthroughs Conference that took place from June 21-23, 2022, in National Harbor, Maryland.

Sientra Wins Premier's Horizon Award for 2022 for Exceptional Customer Service, Engagement, and Value Creation

New Implant Offers Surgeons and Their Patients More Options to Customize Their Surgical Outcomes New Implant Offers Surgeons and Their Patients More Options to Customize Their Surgical Outcomes

FDA Approves Sientra's Low Plus Profile Projection Breast Implant

SANTA BARBARA, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), announced today its participation at the Virtual 19 th Annual Craig-Hallum Institutional Investor Conference, which takes place June 1 st , 2022.

Sientra To Participate At The 19th Annual Craig-Hallum Institutional Investor Conference

Sientra, Inc. (NASDAQ:SIEN ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Oliver Bennett - Senior Vice President, General Counsel & Chief Compliance Officer Ron Menezes - President & Chief Executive Officer Andy Schmidt - Chief Financial Officer Conference Call Participants Margaret Kaczor - William Blair Jason Kreyer - Craig-Hallum Jon Block - Stifel Chris Cooley - Stephens Kyle Bauser - Colliers International Anthony Vendetti - Maxim Group Operator Good day and welcome to this Sientra, Inc. First Quarter 2022 Earnings Conference Call. All participants will be in listen only mode.

Sientra, Inc. (SIEN) CEO Ron Menezes on Q1 2022 Results - Earnings Call Transcript

Sientra (SIEN) delivered earnings and revenue surprises of -11.54% and 5.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Sientra (SIEN) Reports Q1 Loss, Tops Revenue Estimates

SANTA BARBARA, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the first quarter of 2022 after the close of trading on Thursday, May 12, 2022. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.

Sientra to Report First Quarter 2022 Financial Results on May 12, 2022

Blend Labs

Didi Global

Penny stocks with unusual options volume in the stock market today. The post 3 Penny Stocks Investors Are Betting On Big For A Downfall appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Sientra Stock (SIEN)